Where does OCRA's clinical trial data come from?

OCRA indexes clinical trials from ClinicalTrials.gov, the official U.S. registry maintained by the National Library of Medicine. Trials are matched to diseases, investigators, and funded research tracked across the platform.

How do I find clinical trials for ovarian cancer?

Search by condition, treatment type, trial phase, or NCT identifier. Each trial page shows current status, eligibility criteria, study locations, and a direct link to the ClinicalTrials.gov source record.

How often is clinical trial data updated?

Trial data is refreshed through periodic ingestion from the ClinicalTrials.gov v2 API. Status changes, new enrollments, and newly registered trials are captured during each update cycle.

Universal Screening for Lynch Syndrome in Women With Endometrial and Non-Serous Ovarian Cancer

NCT02494791UNKNOWNNAINTERVENTIONAL

Summary

This study will maximize identification of women with Lynch Syndrome using an enhanced screening strategy to identify those at risk. These women will be referred to genetic counselling for testing and those found to have Lynch Syndrome will be asked to invite first degree relatives to participate and undergo genetic testing for Lynch Syndrome. Screening guidelines and risk reducing surgery options for participants found to have Lynch Syndrome will be reinforced by the study and adherence to these guidelines will be assessed annually for ten years following Lynch Syndrome diagnosis to assess the impact and cost-effectiveness of this enhanced screening approach.

Key Facts

Lead Sponsor

University Health Network, Toronto

Enrollment

886

Start Date

2015-07-01

Completion Date

2020-07-01

Study Type

INTERVENTIONAL

Official Title

Universal Screening for Lynch Syndrome in Women With Endometrial and Non-Serous Ovarian Cancer

Interventions

QuestionnaireEducational Material

Conditions

Lynch SyndromeEndometrial NeoplasmsOvarian NeoplasmsColorectal Neoplasms

Eligibility

Age Range

18 Years – 70 Years

Sex

ALL

Inclusion Criteria (Patients):

* 18-70 years old
* endometrial cancer (all grades, stages and histologic subtypes except stromal sarcoma, carcinosarcoma)
* cancer diagnosed within 6 months of consent
* tumour tissue available for MMR IHC
* willing and able to give informed consent for participation in study

Exclusion Criteria (Patients):

* patients under 18 years old or over 70 years old
* patients with uterine adenosarcoma, leiomyosarcoma or endometrial stromal sarcoma
* patients with pure serous or pure mucinous ovarian carcinoma
* patients unwilling or unable to participate in the informed consent process

Inclusion Criteria (First-degree Relatives)

* minimum 18 years old
* reside in Canada
* willing and able to give informed consent for participation in study

Exclusion Criteria (First-degree Relatives):

* under 18 years old
* reside outside of Canada
* unwilling or unable to participate in the informed consent process

Outcome Measures

Primary Outcomes

Adherence to screening guidelines (colonoscopy and gynecologic risk-reducing surgery) in participants found to have Lynch Syndrome

Participants found to have Lynch Syndrome will be followed after diagnosis and asked to update the study annually with information about any colorectal cancer screening (colonoscopy) and/or gynecologic risk-reducing surgery they've undergone. This information will be used to assess the success of the enhanced universal screening protocol in helping treat pre-cancerous lesions and therefore prevent a possible cancer as well as aid in detection of early malignancies that otherwise may have gone undetected.

Time frame: short-term assessment at 1 year after diagnosis, long-term assessment for up to 10 years after diagnosis

Cost-effectiveness of universal enhanced screening strategy to identify women with Lynch Syndrome and their family members via cascade testing

Data about adherence to screening guidelines and the outcome of screening procedures will be used to inform cost-effectiveness models assessing the feasibility of implementing this enhanced universal screening strategy for Lynch Syndrome in institutions across Canada.

Time frame: short-term assessment at 1 year after diagnosis, long-term assessment for up to 10 years after diagnosis

Secondary Outcomes

Incidence of Lynch Syndrome in an unselected group of women with endometrial and non-serous ovarian cancer

This study will add data about the number of Lynch Syndrome cases among a large cohort of endometrial cancer patients in Canada, adding to previous work. This will be the first prospective study to assess Lynch Syndrome incidence in non-serous, non-mucinous ovarian cancer patients in Canada.

Time frame: 3 years

Discovery of novel genetic mutations and molecular events in unexplained MMR loss (Lynch-like Syndrome)

This study will investigate tumour samples from women with unexplained MMR loss (MMR IHC deficient without a germline mutation) to probe what other factors may contribute to Lynch-like Syndrome. Currently these patients are believed to have an intermediate risk for Lynch-associated cancers and are counselled accordingly. Further investigation into the biology of this condition may yield more effective strategies for stratifying and managing risk for Lynch-like Syndrome patients.

Time frame: 3-5 years

Locations

University Health Network - Princess Margaret Hospital, Toronto, Canada